Inherited Retinal Diseases

Latest News

Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501
Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501

June 13th 2024

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Ocugen completes dosing in second cohort of GARDian clinical trial for Stargardt disease
Ocugen completes dosing in second cohort of GARDian clinical trial for Stargardt disease

May 16th 2024

Study: CRIPSR gene editing leads to improvements in vision for people with inherited blindness
Study: CRIPSR gene editing leads to improvements in vision for people with inherited blindness

May 14th 2024

RWC 2024: Longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy for retinitis pigmentosa
RWC 2024: Longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy for retinitis pigmentosa

May 11th 2024

Coave Therapeutics showcases its Aligater platform for generating conjugated AAV vectors to deliver ocular gene therapy through suprachoroidal route
Coave Therapeutics showcases its Aligater platform for generating conjugated AAV vectors to deliver ocular gene therapy through suprachoroidal route

May 1st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.